Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ peripheral blood stem cells
- Development stage
- Phase 2
- Lead developer
- Alejandra Garcia Botella
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Parenteral
01
Overview
Autologous CD133+ peripheral blood stem cells is an investigational cell therapy being evaluated for hepatic regeneration in patients with colorectal cancer liver metastases. The therapy involves mobilizing the patient's own CD133-positive hematopoietic and progenitor stem cells from the peripheral blood, followed by enrichment (typically via immunomagnetic separation) and infusion into the portal vein. This procedure is performed in conjunction with preoperative portal vein embolization (PVE) to stimulate the growth of the future liver remnant (FLR). The goal is to achieve sufficient residual liver volume to allow for safe and feasible major hepatectomy in patients who would otherwise have inadequate liver reserve.
- Other names
- autologous CD133+ hematopoietic stem cellsautologous CD133+ progenitor stem cells
Beyond the preview
Go deeper on autologous CD133+ peripheral blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ peripheral blood stem cells.